Most Read Articles
Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

4 days ago
Breast cancer is the most commonly diagnosed malignancy and leading cause of cancer deaths in Singaporean females. [1] Ninety percent of breast cancers are diagnosed at non-metastatic stages and treated with curative intent. [1] Approximately 70% of newly diagnosed invasive breast cancers are oestrogen receptor (ER) and/or progesterone receptor (PR) positive and human epidermal growth factor receptor-2 (HER2) negative. Overall, these tumors are associated with a favourable clinical behavior, favourable prognosis and with lower risk of recurrence than other breast cancer subtypes. Nevertheless, the risk of recurrence remains, especially with more aggressive tumour biology and increasing tumor burden.
13 Apr 2020
The inherent limitations of using tumour tissues for genomic profiling has led to the need for a more efficient, easily accessible yet accurate method of evaluating biomarkers to facilitate personalised medicine. At the ESMO Asia Colloquia chaired by Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of precision oncology shared insights on the diagnostic, prognostic and predictive values of tumour-derived blood biomarkers (liquid biopsy) for the management of various cancer types.

Liquid biopsy in the management of solid tumours

13 Apr 2020
The inherent limitations of using tumour tissues for genomic profiling has led to the need for a more efficient, easily accessible yet accurate method of evaluating biomarkers to facilitate personalised medicine. At the ESMO Asia Colloquia chaired by Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of precision oncology shared insights on the diagnostic, prognostic and predictive values of tumour-derived blood biomarkers (liquid biopsy) for the management of various cancer types.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Singapore digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

4 days ago
Breast cancer is the most commonly diagnosed malignancy and leading cause of cancer deaths in Singaporean females. [1] Ninety percent of breast cancers are diagnosed at non-metastatic stages and treated with curative intent. [1] Approximately 70% of newly diagnosed invasive breast cancers are oestrogen receptor (ER) and/or progesterone receptor (PR) positive and human epidermal growth factor receptor-2 (HER2) negative. Overall, these tumors are associated with a favourable clinical behavior, favourable prognosis and with lower risk of recurrence than other breast cancer subtypes. Nevertheless, the risk of recurrence remains, especially with more aggressive tumour biology and increasing tumor burden.
13 Apr 2020
The inherent limitations of using tumour tissues for genomic profiling has led to the need for a more efficient, easily accessible yet accurate method of evaluating biomarkers to facilitate personalised medicine. At the ESMO Asia Colloquia chaired by Professor Byoung Chul Cho of Yonsei Cancer Centre, experts in the field of precision oncology shared insights on the diagnostic, prognostic and predictive values of tumour-derived blood biomarkers (liquid biopsy) for the management of various cancer types.